summari ew report underli revenu
underli ahead estim
street respect adj ep
report came consensu
estim ep beat driven effici
product benefici tax rate defer expens ew
underli global thv transcathet heart valv sale
fell short consensu
expect ew thv growth reflect low-
us market growth ou expect
contribut transcathet mitral/tricuspid therapi tmtt
modest regard outlook ew maintain
top-lin guidanc underli
growth includ tavr growth underli
bottom-lin ew increas ep guidanc
addit ew guid sale
estim impli underli growth midpoint
compar consensu estim ew
ep guidanc report bracket
prior street expect previou estim
pipelin front ew continu expect low risk approv later
rais sale estim
underli adj ep estim
came street expect
behind estim tavr sale
estim ww grew slower procedur market
held share sequenti compar regard
us manag said ew growth compar low-doubl
digit market procedur growth ou outsid us ew said tavr
procedur grew slower low-doubl digit market growth
get insight ou market dynam
report earn may ew continu expect
ww tavr sale underli growth
growth ramp year progress low-risk
indic manag said continu expect fda approv
low-risk late
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
tmtt expect contribut transcathet mitral/tricuspid therapi tmtt minim
due on-going cardioband suppli constraint receiv small boost earlier
anticip approv pascal europ manag expect see progress improv
cardioband suppli front work transit product israel ew note
pascal ce mark data expect present upcom dgk german societi cardiolog
europcr tvt meet april may june respect ew said clasp iid
degen mitral regurgit pivot trial continu enrol activ new site
clasp iif function mitral regurgit pivot trial still expect initi late
transcathet mitral valv replac front manag said ew continu enrol
evoqu earli feasibl studi track start sapien pivot trial late
ew continu expect sale contribut tmtt product
sale underli ahead consensu estim
result driven solid aortic unit volum growth continu adopt ew latest premium
surgic heart valv inspiri ew continu expect ssh sale underli
growth behind good despit anticip headwind result result favor
tavr procedur
cc sale underli beat consensu estim
result driven strong perform across categori led hemospher sale ew
recent close acquisit casm non-invas brain tissu oxygen monitor
compani record sale light acquisit good print ew
increas cc sale guidanc prior guidanc continu
guid underli cc sale growth
top-lin outlook re-affirmed ep guidanc rais call ew reiter
guidanc includ total sale underli growth tavr
growth underli ew maintain guid segment thv tmtt ssh increas
expect critic care sale mainli due good start
casm acquisit close april regard currenc expect impact sale fx
continu headwind move ew reiter guidanc
follow item gross margin sg spend sale spend
sale tax rate excl special item bottom-lin ew rais ep guidanc
report report behind good print
casm acquisit ew anticip small impact underli top bottom line
revenu ep guidanc in-lin expect ew guid sale
estim impli underli growth midpoint compar
prior consensu estim ew ep guidanc
report bracket prior street expect previou estim
price target nc
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
